Tofisopam

Tofisopam, a 2,3-benzodiazepine compound, is an orally active anxiolytic agent. Tofisopam can inhibit phosphodiesterase PDE isoenzyme activity, withIC50 values of 2.11 μM, 1.98 μM, 0.42 μM, and 0.92 μM for PDE-2A3, PDE-3A, PDE-4A1, and PDE-10A1, respectively. Tofisopam can be used for the study of anxiety[1][2].

Product Specifications

CAS Number

[22345-47-7]

UNSPSC

12352005

Hazard Statement

H302, H400

Target

Phosphodiesterase (PDE)

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/tofisopam.html

Concentration

10mM

Purity

99.46

Solubility

DMSO : 12.5 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

CC1=NN=C(C2=CC=C(OC)C(OC)=C2)C3=CC(OC)=C(OC)C=C3C1CC

Molecular Formula

C22H26N2O4

Molecular Weight

382.45

Precautions

H302, H400

References & Citations

[1]Rundfeldt C, et al. The atypical anxiolytic drug, tofisopam, selectively blocks phosphodiesterase isoenzymes and is active in the mouse model of negative symptoms of psychosis[J]. Journal of neural transmission, 2010, 117: 1319-1325.|[2]Umut İrfan Üçel, et al. Antiamnesic effects of tofisopam against scopolamine-induced cognitive impairments in rats. Pharmacol Biochem Behav. 2020 Mar;190:172858.